论文部分内容阅读
目的观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法对50例经病理确诊的晚期NSCLC患者,采用培美曲塞500 mg/m2d1+顺铂25 mg/m2d1-3天治疗,21 d为一周期。2个周期后评价疗效、毒副反应。结果患者客观有效率62%,疾病控制率89%,中位无进展生存期9.45个月,中位生存期11.35个月,1a生存率46%;患者毒副反应主要是骨髓抑制、胃肠道反应,均未达到Ⅲ～Ⅳ度。结论培美曲塞联合顺铂一线治疗晚期NSCLC疗效肯定,毒副反应轻,患者耐受性好,临床疗效肯定。
Objective To observe the efficacy and side effects of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Fifty patients with advanced NSCLC diagnosed by pathology were treated with pemetrexed 500 mg / m2d1 and cisplatin 25 mg / m2d1-3 for 21 days. 2 cycles after the evaluation of efficacy, side effects. Results The objective effective rate was 62%, the disease control rate was 89%, the median progression-free survival time was 9.45 months, the median survival time was 11.35 months and the 1a survival rate was 46%. The patients’ side effects were mainly myelosuppression, gastrointestinal tract Reaction, did not reach Ⅲ ~ Ⅳ degrees. Conclusion Pemetrexed combined with cisplatin first-line treatment of advanced NSCLC positive effect, mild side effects, patients with good tolerance, clinical effect is sure.